Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as an “ineligible company”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible company: Any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Speakers / Moderators / Discussants / Authors	Nothing to Disclose	Disclosure
		Company	Role	Received
Katherine Albutt	X
Andrea Alonso	X
Reginald Alouidor	X
Maria Bejar-Chapa	X
Genevieve Boland		Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals, Iovance, Merck, Moderna, Nektar Therapeutics, Novartis, and Ankyra Therapeutics	Consultant, Advisory Board, Equity	Honorarium, Grants, Equity
Marcella Bradway	X
Martin Buta	X
Jahnavi Challagonda	X
Bilal Chaudhry	X
Lilian Chen		Applied Medical	Faculty	Honorarium
Nicole Cherng	X
Megan Chiu	X
Michael DiSiena	X
Robert Driscoll	X
Ali Dzhemiliev	X
Kassra Ehsan	X
Alik Farber		Lemaitre	Consultant/Speaker	Consultant Fees
Heather Ford	X
Anam Furrukh	X
Macie Gettings	X
Camila Guetter	X
Saba Ilkhani	X
Ted James	X
Edward Kelly	X
Kristina Kramer	X
Jennifer LaFemina	X
Anne Larkin	X
Holly Mason	X
Thomas McNamara	X
Cara Michael	X
Attila Nakeeb	X
Faina Nakhlis	X
Claire Ostertag-Hill	X
Leah Ott	X
Aaron Richman	X
Eddy Rios	X
Aymen Sadaka	X
Anupamaa Seshadri	X
Margaret Siu	X
George Velmahos	X
Sarah Wang		NorthSea Therapeutics BV	Presenting Author	Research Funding
Katherine Wasden	X
Benjamin Zendejas		Stryker	Consulting	Honorarium
Planning Committee	Nothing to Disclose	Disclosure
		Company	Role	Received
Muriel Cleary	X
Jennifer Davids		SafeHeal, Tavanta, Medtronic, Olympus	Consultant/Speaker	Honorarium
Michelle McCarthy	X
George Orthopoulos	X
Luise Pernar	X
Hayley Reddington	X
Neal Seymour	X
Jacqueline Wu	X